Acrux's Board is comprised of outstanding achievers in the pharmaceutical industry, finance and business sectors.
Ross Dobinson , BBus. Acc
Ross has been a Director since 1998 and was appointed Chairman in January 2006 and then Executive Chairman from 1 July 2012 to October 2014. He is a founder and former CEO of Acrux. Ross has a background in investment banking and stockbroking. He is currently Managing Director of TSL Group Ltd, a corporate advisory company specialising in establishing and advising life sciences companies. He is a Director of Reliance Worldwide Corporation (ASX: RWC). He was previously a founding Director of Starpharma Holdings Limited (ASX: SPL), Executive Chairman of Hexima Limited (ASX: HXL), Chairman of TPI Enterprises Limited (now Palla Pharma Ltd. ASX: PAL), Director of Roc Oil Company Limited (ASX: ROC) and a Director of Racing Victoria Limited.
Tim Oldham , BSc(Hons), LLB(Hons), PhD
Tim joined the Board in October 2013. He has more than 15 years of life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. Tim is the CEO and MD at AdAlta (ASX: 1AD). AdAlta is an innovative biotech company developing a unique range of new drug treatments. Prior to this, he was Executive Leader of Tijan Ventures, an advisory business focussed on growing life sciences companies through strategic advisory and interim CEO, executive and non-executive leadership services, with a particular focus on cell and gene therapies. He was CEO and Managing Director of Cell Therapies Pty Ltd, a leading contract manufacturer and distributor cellular therapies in Asia Pacific. Tim was President of Asia Pacific for Hospira, Inc., having held a variety of senior management roles with Mayne Pharma Ltd prior to its acquisition by Hospira. These roles encompassed the development and commercialisation of pharmaceuticals, devices, biologics and cellular therapies. Prior to this, Tim was an engagement manager with McKinsey & Co. Tim has been chairman of the European Generic Medicines Association Biosimilars and Biotechnology Committee, a Director of the Alliance for Regenerative Medicine, a Director of the Generic Medicines Industry Association and a member of the Pharmaceutical Industry Strategy Group. He has also been a Director of Respiri Ltd (ASX: RSH) and is a current member of AusBiotech’s Regenerative Medicine Advisory Group.
Michael Kotsanis , BSc, MBus
Chief Executive Officer & Managing Director
Michael has over 30 years of experience in the pharmaceutical industry and has significant senior leadership experience across the global pharmaceutical markets. Michael was formally the Chief Commercial Officer for Synthon Holding BV, an international pharmaceutical company and a leader in the field of generic medicines with revenue over EUR250 million, and was based in the Netherlands, a position he held for four years. Prior to Synthon, he served as President, Europe, Middle East and Africa, for Hospira and where he was responsible for delivering over US$500 million in annual revenue. Hospira was the global leader in generic injectable pharmaceuticals prior to its acquisition by Pfizer. Michael joined Hospira following its acquisition of Mayne Pharma in 2007, where he served as President Asia Pacific from 2002. He joined Mayne following their acquisition of Faulding Pharmaceuticals in 2001, where he held responsibility for commercial activities in Australia and New Zealand. Prior to Faulding, Michael held a variety of sales and marketing positions with Boehringer Ingelheim, a German multinational pharmaceutical company over an 11-year period. Michael earned a Bachelor of Science from Monash University, Melbourne and a Master of Business from the University of Technology, Sydney.
Geoff Brooke , MBBS, MBA
Geoff joined the Board in June 2016. He founded GBS Venture Partners in 1996 and has more than 20 years’ venture capital experience. In January 2014, he reduced his involvement in GBS and is now special adviser to the firm and its funds. Geoff was formally President of Medvest Inc., a US-based early-stage venture capital group he founded with Johnson & Johnson. Geoff's experience includes company formation and acquisitions, as well as public listings on the NYSE, NASDAQ and ASX exchanges. He commenced in March 2017 as Chairman of Actinogen Medical Limited (ASX: ACW) and has been a founder, executive and director of private and public companies. From 2009 until 2015, he was an independent director of the Victoria Workcover Authority. Geoff is licensed in clinical medicine by the Medical Board of Victoria, Australia and his post-graduate work was in anaesthetics and intensive care. He earned his Bachelor of Medicine/Surgery from the University of Melbourne, Australia and a Masters of Business Administration from IMEDE (now IMD) in Lausanne, Switzerland.
Simon Green , Ph.D.
Simon joined the Board in June 2016. He is an experienced biotechnology professional with expertise in drug development, having worked at Genentech and Novartis in San Francisco before joining CSL Limited in 1998. At CSL, Simon held several roles in project and portfolio management before being promoted to Senior Vice President of Global Research and Development for CSL Behring. He also held roles as General Manager of CSL Behring’s plasma products manufacturing operations in Germany and Australia. Simon left CSL in November 2015 to start up a biotech company, Immunosis Pty Ltd, focused on improved diagnostic outcomes for patients with immune deficiencies. He also founded a consultancy service providing advice to companies in the plasma products field. Simon graduated from Monash University and completed his PhD in the field of immunology at Melbourne University in 1992. He is a graduate of the Australian Institute of Company Directors and previously held Board governance roles for several CSL subsidiary companies in Australia and Germany and for the European Plasma Protein Therapeutics Association. Simon has provided strategic advice to Government through his membership of the Victorian Biotechnology Advisory Council and Northern Innovation and Investment Fund.